Article

The genomic structure and promoter region of the human parkin gene.

Department of Molecular Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Biochemical and Biophysical Research Communications (Impact Factor: 2.28). 10/2001; 286(5):863-8. DOI: 10.1006/bbrc.2001.5490
Source: PubMed

ABSTRACT Parkin has been identified as a causative gene of the autosomal recessive juvenile parkinsonism (AR-JP). In this study, we determined the genomic structure of the Parkin gene and identified a core promoter region based on the DNA sequence of 1.4 Mb. The 5'-flanking region contained no apparent TATA or CAAT box elements but several putative cis-elements for various transcription factors. The GC- and CpG-rich regions were observed not only in the 5'-flanking sequence but also in the 5'-part of the first intron of Parkin. We identified an exact starting point of Parkin transcription. A core promoter region was determined by transfecting a series of deletion constructs with a dual luciferase reporter system into human neuroblastoma cells. Furthermore, we located a neighboring novel gene in a head-to-head direction with Parkin with only a 198-bp interval.

0 Followers
 · 
66 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Various mutations in the PARK2 gene which encodes the protein, parkin, are causal of a disease entity-termed autosomal recessive juvenile parkinsonism. Parkin can function as an E3 ubiquitin-protein ligase, mediating the ubiquitination of specific targeted proteins and resulting in proteasomal degradation. Parkin is thought to lead to parkinsonism as a consequence of a loss in its function. In this study, immunoblot analyses of brain extracts from Balb/c, C57BL/6, C3H, and 129S mouse strains demonstrated significant variations in immunoreactivity with anti-parkin monoclonal antibodies (PRK8, PRK28, and PRK109). This resulted partly from differences in the steady-state levels of parkin protein across mouse strains. There was also a complete loss of immunoreactivity for PRK8 and PRK28 antibodies in C3H mice due to was because of a homologous nucleotide mutation resulting in an E398Q amino acid substitution. In cultured cells, parkin harboring this mutation had a greater tendency to aggregate, exhibited reduced interaction with the E2 ubiquitin-conjugating enzymes, UbcH7 and UbcH8, and demonstrated loss-of-function in promoting the proteosomal degradation of a specific putative substrate, synphilin-1. In situ, C3H mice displayed age-dependent increased levels of brain cortical synphilin-1 compared with C57BL/6, suggesting that E398Q parkin in these mice is functionally impaired and that C3H mice may be a suitable model of parkin loss-of-function similar to patients with missense mutations.
    Journal of Neurochemistry 04/2010; 113(2):402-17. DOI:10.1111/j.1471-4159.2010.06605.x · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The recent linkage of genetic mutations in the parkin gene to familial Parkinsonís disease (PD) and the seminal discovery that parkin functions as an ubiquitin ligase associated with the ubiquitin-proteasome system have been instrumental in shaping our understanding of PD pathogenesis. Currently, mutations in parkin are recognised as the most common cause of familial PD. Emerging evidence also suggests a role for parkin in dopaminergic neuronal dysfunction as well as Lewy body biogenesis in the more common sporadic PD. The relevance of parkin in PD is thus compelling. In this review, we highlight several significant discoveries made recently regarding parkin function that support its role in both familial and idiopathic PD. We will also discuss the phenotypes of a number of mouse models of parkin function that have been generated based on the targeted ablation of the parkin gene.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The hypothesis that heredity plays an important role in the etiology of PD has long seemed attractive. It was initially suggested by positive family histories and later by reports of kindreds of "parkinsonism." It was reinforced by the first systematic family study of PD conducted a half-century ago by Mjones. However, closer study of the clinical data indicates that familial aggregations of parkinsonism have reflected various other disorders, notably OPCA and other forms of multiple system atrophy. Case control studies have failed to document a prevalence of PD among first-degree relatives of index cases significantly exceeding that found in control groups. More recently, the concordance rate for PD among monozygotic twins has been found to be unexpectedly low and not significantly different from that among dizygotic twins or the prevalence among first-degree relatives. Thus, the best available data do not support a role of heredity in the etiology of PD. A nonhereditary, possibly congenital genetic defect is, however, not excluded.
    Science 12/1997; 278(5341):1212-3. · 31.48 Impact Factor